JP5286255B2 - カンナビゲロールを含有する医薬組成物のうつ病の治療のための使用 - Google Patents

カンナビゲロールを含有する医薬組成物のうつ病の治療のための使用 Download PDF

Info

Publication number
JP5286255B2
JP5286255B2 JP2009514901A JP2009514901A JP5286255B2 JP 5286255 B2 JP5286255 B2 JP 5286255B2 JP 2009514901 A JP2009514901 A JP 2009514901A JP 2009514901 A JP2009514901 A JP 2009514901A JP 5286255 B2 JP5286255 B2 JP 5286255B2
Authority
JP
Japan
Prior art keywords
cbg
cannabigerol
cannabinoids
depression
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009514901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539961A (ja
JP2009539961A5 (https=
Inventor
リチャード・マスティ
リチャード・デヨ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of JP2009539961A publication Critical patent/JP2009539961A/ja
Publication of JP2009539961A5 publication Critical patent/JP2009539961A5/ja
Application granted granted Critical
Publication of JP5286255B2 publication Critical patent/JP5286255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2009514901A 2006-06-15 2007-06-14 カンナビゲロールを含有する医薬組成物のうつ病の治療のための使用 Active JP5286255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81381406P 2006-06-15 2006-06-15
US60/813,814 2006-06-15
PCT/GB2007/002216 WO2007144628A1 (en) 2006-06-15 2007-06-14 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression

Publications (3)

Publication Number Publication Date
JP2009539961A JP2009539961A (ja) 2009-11-19
JP2009539961A5 JP2009539961A5 (https=) 2010-07-29
JP5286255B2 true JP5286255B2 (ja) 2013-09-11

Family

ID=38353631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514901A Active JP5286255B2 (ja) 2006-06-15 2007-06-14 カンナビゲロールを含有する医薬組成物のうつ病の治療のための使用

Country Status (5)

Country Link
US (2) US8481085B2 (https=)
EP (1) EP2037901B1 (https=)
JP (1) JP5286255B2 (https=)
CA (1) CA2655094C (https=)
WO (1) WO2007144628A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2471190T3 (es) * 2003-06-24 2014-06-25 Gw Pharma Limited Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US20100293021A1 (en) * 2009-01-23 2010-11-18 Intranet Productivity Solutions, Ltd. Method and system for task tracking and allocation
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US10045540B2 (en) 2014-04-01 2018-08-14 Fayetteville State University Pest control composition
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3576724B1 (en) 2017-02-01 2023-09-27 GBS Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
CA3085007C (en) * 2017-12-08 2021-12-21 Biotech Institute LLC High cannabigerol cannabis plants, methods of producing and methods of using them
EP3745884A1 (en) * 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CN112969452A (zh) 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
IL326299A (en) * 2018-10-31 2026-04-01 Baymedica Inc Cannabinoid analogs and methods for their preparation
CA3129535A1 (en) 2019-03-07 2020-09-10 Oludare ODUMOSU Formulations for treating cluster symptoms associated with autism spectrum disorder
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
JP2022551476A (ja) * 2019-10-08 2022-12-09 ベッソール ファルマ、エルエルシー カンナビノイド及びカンナビノイド酸の製造プロセス
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
EP4065554A4 (en) * 2019-11-26 2024-01-10 Canopy Growth Corporation CANNABIGEROL DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS
JP2023503330A (ja) * 2019-11-26 2023-01-27 キャノピー グロウス コーポレイション カンナビノイド誘導体
WO2021113958A1 (en) * 2019-12-09 2021-06-17 Canopy Growth Corporation Cannabinoid derivatives
US11767306B2 (en) 2020-01-17 2023-09-26 Cannacraft, Inc Methods for converting CBD to tetrahydrocannabinols
EP4121164A1 (en) * 2020-03-17 2023-01-25 Tauriga Sciences Inc. Medicated cannabinoid compositions, methods of manufacturing, and methods of treatment
US11786838B2 (en) * 2020-03-23 2023-10-17 Cannacraft, Inc. Methods for removing pesticides from Cannabis products
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
WO2022147270A1 (en) 2020-12-31 2022-07-07 Cookies Creative Consulting & Promotions, Inc. Compositions comprising cannabis and mushroom extracts, and uses thereof
US11465957B1 (en) 2021-04-08 2022-10-11 MYKU Biosciences LLC Methods and systems for crystallizing and isolating individual cannabinoids
US11345650B1 (en) 2021-04-08 2022-05-31 MYKU Biosciences LLC Methods and systems for crystallizing and isolating individual cannabinoids
CN115504862B (zh) * 2021-06-07 2024-07-05 南通新世元生物科技有限公司 一种大麻萜酚的制备方法
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same
WO2024015780A1 (en) 2022-07-11 2024-01-18 Ilera Therapeutics Llc Zlt-007 and methods of treating diabetic neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002056932A2 (en) * 2000-10-27 2002-07-25 Emlin Biosciences Thermal vaporizing device for drug delivery
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
AU2003240824B9 (en) * 2002-05-31 2008-09-25 University Of Mississippi Transmucosal delivery of cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
ES2471190T3 (es) 2003-06-24 2014-06-25 Gw Pharma Limited Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno

Also Published As

Publication number Publication date
EP2037901A1 (en) 2009-03-25
CA2655094A1 (en) 2007-12-21
CA2655094C (en) 2014-09-30
US20080031977A1 (en) 2008-02-07
US20140039043A1 (en) 2014-02-06
JP2009539961A (ja) 2009-11-19
WO2007144628A1 (en) 2007-12-21
EP2037901B1 (en) 2014-01-08
US8481085B2 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
JP5286255B2 (ja) カンナビゲロールを含有する医薬組成物のうつ病の治療のための使用
JP5226053B2 (ja) ベンジルイソキノリン誘導体またはビスベンジルイソキノリン誘導体を含有する向精神薬、鎮痛薬および／または抗炎症薬、ならびに健康食品
US20090306221A1 (en) Use for Cannabinoid
US20100292345A1 (en) Therapeutic uses of cannabigerol
US12115137B2 (en) Synergistic combinations of atorvastatin and cannabidiol (CBD)
KR20230121776A (ko) 아마니타 무스카리아 화합물
RU2395293C2 (ru) Фармацевтическая композиция для лечения депрессии и способ ее получения
US11504350B2 (en) Cannabinoid compositions and methods of use thereof
AU2025226742A1 (en) Compositions for regulating homeostasis of cortisol and improving sleep quality and methods of use and production thereof
US8470874B2 (en) Pharmaceutical compositions comprising cannabichromene type compounds
CN101590065A (zh) 西伯利亚远志糖A1、西伯利亚远志糖A5和tenuifoliside A在制备治疗抑郁症产品中的应用
WO1988008702A1 (en) Medicament for schizophrenia
WO2009140859A1 (zh) 左旋千金藤啶碱(l-spd)衍生物的用途
US20170209415A1 (en) Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive disorders including nicotine addiction
NL2022615B1 (en) Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
Komsta et al. Biological background of designer drugs
KR100592489B1 (ko) 잠분을 함유하는 항비만용 약제학적 조성물
CN119326746A (zh) 一种盐酸维拉帕米在制备抗prrsv药物中的应用
KR100615532B1 (ko) 잠분을 함유하는 신경안정용 약제학적 조성물
HK1084670B (en) Pharmaceutical compositions comprising cabbinochreme type compounds
CN114159438A (zh) 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物
JPH02292234A (ja) 新規ジテルペンキノン及び該化合物を有効成分とするアルドースレダクターゼ阻害剤
Espay Toxic Movement Disorders: The Approach
BRPI0900614A2 (pt) extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção
HK1100642A (en) Method of making antitussive medicine and relieving cough

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130603

R150 Certificate of patent or registration of utility model

Ref document number: 5286255

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250